FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ -- Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane ® Defyne for the augmentation and correction of mild to ...

Results showed that 74% of Restylane Defyne-treated patients achieved significantly improved chin projection for up to 1 year. The Food and Drug Administration (FDA) has approved Restylane ® Defyne ...

Hyaluronic acid 20mg/mL, lidocaine 3mg/mL; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...

There's a new filler in town (actually, two new fillers) and they're billed as the next big thing in the fight against laugh lines. Galderma, the pharmaceutical company behind injectables like ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Restylane Defyne for mild to moderate chin retrusion augmentation in adults older than 21 ...

(MENAFN- PR Newswire) FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ -- Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane® Defyne for the augmentation and ...

Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, ...